Arthur Fils did THIS on back to back points against Vacherot in Miami.
Insane slice forehand passing shot. 🤯
Massive forehand winner.
The celebration… He’s just aura farming now 😮💨😤
Would the Crimson publish: “Should I let go of my Muslim friends?” or, “Should I let go of my gay friends?” If they would, read the published response to letting go of Zionist friends, and replace Zionism and Zionist with Islam and Muslim, ask yourself if the “Amateur Ethicist” would respond this way if it was about letting go of Muslim or gay friends?
(Many will try to argue that it’s not a fair comparison. I posit that it’s in their argument that the double standard and bias will further emerge.)
Longtime Chris Sailer Kicking Kicker @AJSalo_9 is having a big senior year and his hard work is paying off. He now holds offers from Columbia, Cornell, University of Chicago & Carnegie Mellon. AJ is the definition of Student-Athlete. @3PointKicking#TeamSailer
Standard models usually treat cell membranes as infinitely thin, but finite thickness fundamentally alters their physics. Membrane bending induces shear flows, reversals, & pressure inversion, effects missed in 2D models but captured with finite thickness
https://t.co/AjzFg5P8Hm
Everyone should read this. Wish I could RT 1,000x
Invaluable insight into the rigorous truth-seeking & intellectual flexibility that the best biotech investors bring to company & asset diligence; and the objectivity with which they reflect on / learn from hits & misses alike
Dan / ADAR1 are rarely wrong - adhering to a process like this is a big reason why
Thank you for sharing @Biohazard3737
People often say biotech never had its own "Bell Labs," but it actually did: the Novartis Institutes for Biomedical Research.
My new piece about what made NIBR special, why it succeeded, and why pharma eventually turned away from its own breakthrough:
Over the past 100 years, science and research have become the building blocks of America’s extraordinary strength.
In less than 100 days, President Trump has undermined that strength — and opened the door for China, with its growing scientific prowess, to be the beneficiary.
My take:
@NightOwlBiotech This is very interesting but would prefer to see EV multiples for the 5 commercial names (Jazz, etc.) so we can do apples to apples. I get that others don’t have as much debt but still would like to do h2h comparison
On regulatory uncertainty - one topic that’s often overlooked (not just on this pod, which I’m a big fan of) is the impact of cuts to academia. Ongoing administrative strife is driving a real-time brain drain that will ripple through startups and biopharma for years to come...